Sound Income Strategies LLC Sells 20,005 Shares of Pfizer Inc. $PFE

Sound Income Strategies LLC trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.4% in the 3rd quarter, Holdings Channel reports. The firm owned 818,064 shares of the biopharmaceutical company’s stock after selling 20,005 shares during the quarter. Pfizer accounts for 1.1% of Sound Income Strategies LLC’s holdings, making the stock its 22nd biggest holding. Sound Income Strategies LLC’s holdings in Pfizer were worth $20,648,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the stock. Capital Advisory Group Advisory Services LLC raised its stake in shares of Pfizer by 2.9% during the second quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock valued at $328,000 after acquiring an additional 388 shares in the last quarter. Citizens National Bank Trust Department raised its position in Pfizer by 0.9% during the 2nd quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company’s stock valued at $1,118,000 after purchasing an additional 395 shares in the last quarter. Peak Asset Management LLC grew its position in shares of Pfizer by 1.4% during the 2nd quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock worth $697,000 after buying an additional 402 shares in the last quarter. Able Wealth Management LLC increased its stake in shares of Pfizer by 2.0% during the second quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company’s stock valued at $512,000 after buying an additional 413 shares during the period. Finally, Boltwood Capital Management raised its holdings in shares of Pfizer by 0.7% in the third quarter. Boltwood Capital Management now owns 58,274 shares of the biopharmaceutical company’s stock valued at $1,485,000 after acquiring an additional 420 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Scotiabank reaffirmed a Buy on PFE, signaling continued analyst conviction from some firms despite the weak outlook. Scotiabank Reaffirms Buy
• Positive Sentiment: Pfizer moved to strengthen its obesity pipeline by licensing a weight-loss drug from Fosun, a strategic push into a high-growth market that could drive medium-term revenue upside if commercialization succeeds. Pfizer licenses weight-loss drug from Fosun
• Positive Sentiment: New liver cancer trial update suggests potential longer-term oncology upside, adding to the narrative that successful Phase III execution could materially re-rate the stock over time. Pfizer’s New Liver Cancer Trial
• Neutral Sentiment: Analysts and industry write-ups (MarketBeat, Benzinga comparisons, and Motley Fool pieces) are weighing PFE versus peers (Merck, Eli Lilly) — useful context but varied conclusions; these pieces emphasize that Pfizer’s future returns hinge on pipeline execution and commercial recovery. Better Buy in 2026: Pfizer or Merck?
• Neutral Sentiment: One analyst summary notes PFE looks materially undervalued with a high forward yield, but warns upside is conditional on successful late‑stage trials and commercialization. This frames PFE as a yield/turnaround play rather than immediate growth. Pfizer Isn’t Dead Money
• Negative Sentiment: Pfizer issued a muted 2026 outlook and trimmed profit guidance, citing lower COVID sales and patent/exclusivity pressures; that guidance and the revenue/profit trims are the primary reasons shares fell today. Pfizer Down After Muted 2026 Outlook
• Negative Sentiment: Following the outlook, some brokers cut or softened ratings (average brokerage rating now around Hold), and the stock has taken analyst downgrades and short‑term selling pressure. Average Rating of Hold from Brokerages
• Negative Sentiment: High-profile commentary (Jim Cramer) highlighting management struggles adds to negative sentiment and short-term headline risk after the guidance release. Jim Cramer: CEO Struggling

Pfizer Stock Up 0.6%

Shares of PFE stock opened at $25.19 on Friday. The stock’s fifty day moving average price is $25.10 and its 200 day moving average price is $24.84. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.69. The company has a market cap of $143.22 billion, a price-to-earnings ratio of 14.65 and a beta of 0.46. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The business had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. Pfizer’s dividend payout ratio (DPR) is currently 100.00%.

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent research reports. Sanford C. Bernstein reiterated a “market perform” rating and set a $30.00 target price on shares of Pfizer in a report on Friday, October 31st. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Bank of America reduced their price objective on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Finally, Morgan Stanley dropped their price objective on Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Friday, December 12th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $28.06.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.